(Q44897788)

7 December 2017

title

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection (English)

1 reference

7 December 2017

main subject

Clostridium difficile

0 references

1 reference

4

1 reference

7 December 2017

6

Mark H Wilcox

0 references

author name string

Grace S Crowther

1

1 reference

7 December 2017

Simon D Baines

2

1 reference

7 December 2017

Sharie L Todhunter

3

1 reference

7 December 2017

Caroline H Chilton

5

1 reference

7 December 2017

language of work or name

English

0 references

publication date

10 September 2012

1 reference

Journal of Antimicrobial Chemotherapy

7 December 2017

published in

1 reference

7 December 2017

volume

68

1 reference

7 December 2017

issue

1

1 reference

7 December 2017

page(s)

168-176

1 reference

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Reduced susceptibility of Clostridium difficile to metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Validation of a Three-Stage Compound Continuous Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism of Bacteria in the Human Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS359

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS359

1 reference

7 December 2017

1 reference